GSK plc (NYSE:GSK) Receives $50.00 Average Target Price from Analysts

Shares of GSK plc (NYSE:GSK) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $50.00.

A number of brokerages have commented on GSK. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On GSK

Institutional investors and hedge funds have recently made changes to their positions in the stock. JTC Employer Solutions Trustee Ltd lifted its position in GSK by 71.3% in the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after acquiring an additional 8,800,822 shares in the last quarter. Primecap Management Co. CA lifted its position in GSK by 13.9% in the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after acquiring an additional 1,773,020 shares in the last quarter. Mondrian Investment Partners LTD lifted its position in GSK by 37.8% in the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after acquiring an additional 1,512,442 shares in the last quarter. Acadian Asset Management LLC lifted its position in GSK by 180.0% in the 1st quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock valued at $95,129,000 after acquiring an additional 1,426,935 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in GSK in the 2nd quarter valued at about $52,487,000. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK stock opened at $37.01 on Thursday. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. GSK has a twelve month low of $33.67 and a twelve month high of $45.92. The stock has a market cap of $76.70 billion, a price-to-earnings ratio of 13.41, a P/E/G ratio of 1.23 and a beta of 0.65. The company’s fifty day moving average is $40.88 and its 200 day moving average is $41.08.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The company had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. Sell-side analysts forecast that GSK will post 4.14 EPS for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.